STANDARD TREATMENT WORKFLOW (STW)

Chronic Obstructive Pulmonary Disease

Surinder Jindal[1], G.C. Khilnani[2], Ashutosh Aggarwal[3], Anant Mohan[4], Raj Kumar[5], Alok Nath[6], Dhruv Chaudhary[7], Uma Mohan[8], DJ Christopher[9], Deepak Talwar[10]

[1]Postgraduate Institute of Medical Education and Research, Chandigarh; [2]All India Institute of Medical Sciences. New Delhi; [3]Postgraduate Institute of Medical Education and Research, Chandigarh; [4]All India Institute of Medical Sciences. New Delhi; [5]Vallabhbhai Patel Chest Institute, New Delhi; [6]Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow; [7]Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak; [8]St John's Medical College, Bengalluru; [9]Christian Medical College Vellore; [10]Metro Hospital, Noida

CORRESPONDING AUTHOR

Dr Surinder Jindal, Postgraduate Institute of Medical Education and Research, Chandigarh

Email: dr.skjindal@gmail.com

CITATION

Jindal S, Khilnani GC, Aggarwal A, Mohan A, Kumar R, Nath A, Chaudhary D, Mohan U, Christopher DJ, Talwar D. Chronic Obstructive Pulmonary Disease. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S171-S172. DOI: https://doi.org/10.56450/JEFI.2024.v2i1Suppl.086

This work is licensed under a Creative Commons Attribution 4.0 International License.

©The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.



October/ 2019

Department of Health Research
Ministry of Health and Family Welfare, Government of India

ICMR INDIAN COUNCIL OF MEDICAL RESEARCH
Serving the nation since 1911

Standard Treatment Workflow (STW) for the Management of
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

ICD-10-J44.9



DIAGNOSIS & SEVERITY ASSESSMENT

Airway obstruction should be documented on spirometry on all patients provisionally diagnosed as having COPD – refer if necessary. Post-bronchodilator FEV1/ FVC <0.70 defines airflow obstruction

Assess severity based on spirometry, severity of dyspnea (mMRC scale, Table 1), exacerbation frequency and presence of complications (see Table 2)

TREATMENT

- Advice smoking cessation and counsel for other risk factors
- Inhaled drugs are the mainstay
- Treatment based on severity assessment (See adjacent figure)
- Follow up: Mild to moderate disease - 3 to 6 Months; Severe disease - 1-3 months
- Ensure compliance and proper inhaler technique at each visit.
- If uncotrolled/ complications develop, refer to higher center



Refer if inadequate response, onset of new complications, or suspicion of alternative diagnosis

DISEASE EXACERBATION

Three cardinal symptoms:
- Increase in dyspnea
- Increase in sputum volume and/or
- Increse in sputum purulence

Classify As:
- Mild Exacerbation
- Severe Exacerbation

Features Of Severe Exacerbation:
- Cyanosis
- Respiratory rate >30/ min
- Heart rate >110/min
- Systolic blood pressure <90 mm Hg
- SpO2 <90%
- Paradoxical respiratory movements
- Altered sensorium
- Asterixis
- Presence of severe co-morbid conditions (e.g. heart failure, arrhythmia)

MILD EXACERBATION
- Increase dose and/ or frequency of levosalbutamol and/ or ipratropium inhalation, or nebulized levosalbutamol/ ipratropium (1.25 mg/ 0.5 mg), repeated as needed at 20-minute interval
- Amoxycillin 500 mg TDS/ Azithromycin 500 mg OD/ Doxycycline 100 mg OD (BD on day 1) X 5 Days
- Oral prednisolone 30 mg daily X 5 days

SEVERE EXACERBATION
Treatment as under Mild Exacerbation
+
Supplement oxygen with target spO2 of 92% (if spO2 monetoring available)

TABLE 1. GRADING OF BREATHLESSNESS USING MODIFIED MEDICAL RESEARCH COUNCIL (MMRC) SCALE.

GRADE	DESCRIPTION OF BREATHLESSNESS
0	I only get breathless with strenuous exercise.
1	I get short of breath when hurrying on level ground or walking up a slight hill.
2	On level ground, I walk slower than people of the same age because of breathlessness or have to stop for breath when walking at my own pace.
3	I stop for breath after walking about 100 yards or after a few minutes on level ground.
4	I am too breathless to leave the house or I am breathless when dressing.

TABLE 2. SEVERITY CLASSIFICATION FOR COPD

SEVERITY	POSTBRONCHODILATOR FEV1 (% PREDICTED)	DYSPNEA (MMRC GRADE)	EXACERBATIONS IN LAST ONE YEAR	COMPLICATIONS*
MILD	≥ 80	<2	<2	NO
MODERATE	50-79	≥ 2	<2	NO
SEVERE	<50	≥ 2	≥ 2	YES

The category with the worst value should be used for severity classification
*Complications include respiratory failure, cor pulmonale, and secondary polycythemia

RED FLAG SIGNS FOR PEOPLE HAVING EXCERBATION
- Altered sensorium
- spO2 <88% despite therapy
- Heart rate >110 bpm
- Systolic blood pressure <90 mm Hg
- High risk comorbid conditions (arrhythmia, congestive cardiac failure, poorly controlled diabetes, renal or liver failure)

Refer to higher centre for further management, and ensure continued supplemental oxygen and nebulization during transfer

SCHEDULE FOLLOW UP VISIT ONE WEEK AFTER DISCHARGE

ADMISSION CRITERIA
1. Severe symptoms; sudden worsening of resting dyspnea.
2. Fall in oxygen saturation, cyanosis, confusion, drowsiness.
3. Failure of an exacerbation to respond to initial medical management.
4. Presence of serious comorbidities (heart failure, newly occurring arrhythmias, etc.)

DISCHARGE CRITERIA
1. Normalization of clinical and laboratory data to pre-admission levels
2. Patient able to follow maintenance therapy
3. Completion of acute medications
4. Adequate control of comorbidities

KEEP A HIGH THRESHOLD FOR INVASIVE PROCEDURES

REFERENCES

1. Gupta D, et al. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/ NCCP(I) recommendations. Lung India 2013;30:228-67
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report.
3. National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2018.

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit our web portal (stw.icmr.org.in) for more information.
© Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Government of India.